Investigation of the Safety Profiles of Japanese Clinical Trials.
The increasing attrition rates of new drug research and development have become a global problem. To tackle this problem as well as the problem of "drug lag" in Japan, strategies utilizing multiregional clinical trials (MRCTs) are now being commonly applied. It is important to determine whether clinical data in a specific country and region have tendencies or patterns that will help us to consider an appropriate strategy for drug development in the specific region as well as worldwide. However, little has been studied on strategies and methods for drug development to pursue simultaneous development taking into account these characteristics. It would be valuable to determine and characterize the safety profile of Japanese clinical trial data. To characterize the overall safety profile of Japanese data in terms of the frequency of adverse events (AEs), serious AEs, and discontinuation due to AEs compared with non-Japanese data, 73 pharmaceutical products recently approved in Japan were selected. Their clinical trial safety data, derived from comparable studies conducted in Japan and Western countries using the bridging strategy and MRCTs, were reviewed and analyzed. Japanese data are similar to non-Japanese data in terms of overall frequency of AEs; however, the sample size of Japanese patients in the bridging studies and MRCTs was generally smaller than that in non-Japanese data. The safety profile in Japanese clinical data was shown to be similar to that of non-Japanese data from the standpoint of overall frequency of AEs. This finding should be encouraging to pharmaceutical companies and the health authority in Japan to accelerate participation in MRCTs.